All In Biotech

Drug Trial Radar · NCT01650805

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Last checked: Nov 20, 2026Latest source record: Nov 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

307

Actual

Start

Jun 2012

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Ariad PharmaceuticalsTakeda (TAK)
Sponsor type
Industry
First posted
Jul 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • ponatinibDrug

    45 mg tablet, taken orally once daily

  • imatinib (Gleevec/ Glivec)Drug

    400 mg tablet, taken orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Molecular Response (MMR) Rate at 12 MonthsTime frame: 12 months after first dose

Locations

170 sites in 24 countries. Site status is shown where the registry gives one.

  • US Oncology - Providence Health System, Site #167

    Burbank, California

  • UCLA Department of Medicine, Site #027

    Los Angeles, California

  • Bay Area Cancer Research Group, Site #156

    Pleasant Hill, California

  • Bay Area Cancer Research Group, Site #157

    Pleasant Hill, California

  • Rocky Mountain Cancer Centers, Site #191

    Boulder, Colorado

  • Cancer Center of Central Connecticut, Site #147

    Southington, Connecticut

  • Christiana Care Health Services, Site #155

    Newark, Delaware

  • University Cancer Institute, Site #149

    Boynton Beach, Florida

  • Florida Cancer Specialists, Site #180

    Fort Meyers, Florida

  • Florida Cancer Specialists, Site #179

    St. Petersburg, Florida

  • Emory University, Site #058

    Atlanta, Georgia

  • John H. Stroger, Jr. Hospital of Cook County, Site #192

    Chicago, Illinois

  • University of Chicago, Site #001

    Chicago, Illinois

  • Loyola University Chicago, Site #054

    Maywood, Illinois

  • Franciscan St. Francis Health, Site #138

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics, Site #050

    Iowa City, Iowa

  • Siouxland Hematology-Oncology Associates, Site #198

    Sioux City, Iowa

  • US Oncology - Cancer Center of Kansas, Site #168

    Wichita, Kansas

  • Willis-Knighton Cancer Center, Site #196

    Shreveport, Louisiana

  • University of Maryland, Greenebaum Cancer Center, Site #040

    Baltimore, Maryland

  • Greater Baltimore Medical Center, Site #140

    Baltimore, Maryland

  • St. Agnes Healthcare, Site #185

    Baltimore, Maryland

  • Massachusetts General Hospital, Site #047

    Boston, Massachusetts

  • Dana Farber Cancer Institute, Site #008

    Boston, Massachusetts

  • University of Massachusetts Worcester, Site #152

    Worcester, Massachusetts

  • University of Michigan Medical Center, Site #011

    Ann Arbor, Michigan

  • Providence Cancer Institute, Site #197

    Southfield, Michigan

  • Mayo Clinic, Site #044

    Rochester, Minnesota

  • Oncology Research Park Nicollet Institute, Site #195

    Saint Louis Park, Minnesota

  • Saint Luke's Hospital, Site #162

    Kansas City, Missouri

  • Mercy Clinic - Cancer & Hematology, Site #151

    Springfield, Missouri

  • Nebraska Hematology-Oncology, P.C., Site # 133

    Lincoln, Nebraska

  • US Oncology - Comprehensive Cancer Center of Nevada, Site #169

    Las Vegas, Nevada

  • John Theurer Cancer Center, Site #128

    Hackensack, New Jersey

  • University of New Mexico Cancer Center, Site #166

    Albuquerque, New Mexico

  • Maimonides Cancer Center, Site #177

    Brooklyn, New York

  • Winthrop University Hospital, Site #153

    Mineola, New York

  • Beth Israel Medical Center, Site #145

    New York, New York

  • Mount Sinai School of Medicine, Site #189

    New York, New York

  • Memorial Sloan-Kettering Cancer Center, Site #078

    New York, New York

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.